Literature DB >> 26279846

Management of Crohn's disease - are guidelines transferred to clinical practice?

Thomas Klag1, Eduard F Stange2, Jan Wehkamp3.   

Abstract

BACKGROUND: Management of Crohn's disease (CD) is a clinical challenge. In terms of an evidence-based approach, clinical guidelines help to deal with this challenge. However, little is known about guideline adherence concerning the management of CD in Germany.
OBJECTIVE: To survey German gastroenterologists with regards to their guideline adherence in daily clinical care.
METHOD: A web-based national survey was conducted among German gastroenterologists.
RESULTS: A total of 175 inflammatory bowel disease (IBD) practitioners responded to the survey. Overall, in the different clinical situations covered in the questionnaire guideline adherence is good. However, the 5-aminosalicylic acid (5-ASA) prescribing habits represent a striking exception. About 10-36% use 5-ASA as mono-therapy in CD, depending on the clinical scenario. Predominantly it is used in mild CD and in colonic involvement. To maintain a surgically achieved remission, therapeutic decisions broadly rely on individual approaches with azathioprine and 5-ASA being used by about 30% of the respondents. Cessation of smoking as a "therapeutic" strategy of maintenance therapy is used by only half of the surveyed physicians.
CONCLUSION: Amongst German IBD practitioners, the guideline adherence is good overall. Reflecting ongoing uncertainty about the efficacy of mesalazine, its use in Crohn's disease is still heterogeneous.

Entities:  

Keywords:  5-aminosalicylic acid; Crohn’s disease; Inflammatory bowel disease; clinical guidelines; clinical practice; survey

Year:  2015        PMID: 26279846      PMCID: PMC4528212          DOI: 10.1177/2050640615580228

Source DB:  PubMed          Journal:  United European Gastroenterol J        ISSN: 2050-6406            Impact factor:   4.623


  26 in total

1.  The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management.

Authors:  A Dignass; G Van Assche; J O Lindsay; M Lémann; J Söderholm; J F Colombel; S Danese; A D'Hoore; M Gassull; F Gomollón; D W Hommes; P Michetti; C O'Morain; T Oresland; A Windsor; E F Stange; S P L Travis
Journal:  J Crohns Colitis       Date:  2010-01-15       Impact factor: 9.071

2.  [Clinical practice guideline on diagnosis and treatment of Crohn's disease].

Authors:  J C Hoffmann; J C Preiss; F Autschbach; H J Buhr; W Häuser; K Herrlinger; W Höhne; S Koletzko; C F Krieglstein; W Kruis; H Matthes; G Moser; M Reinshagen; G Rogler; S Schreiber; A G Schreyer; B Sido; B Siegmund; A Stallmach; B Bokemeyer; E F Stange; M Zeitz
Journal:  Z Gastroenterol       Date:  2008-09-22       Impact factor: 2.000

3.  Patients enrolled in randomized controlled trials do not represent the inflammatory bowel disease patient population.

Authors:  Christina Ha; Thomas A Ullman; Corey A Siegel; Asher Kornbluth
Journal:  Clin Gastroenterol Hepatol       Date:  2012-02-15       Impact factor: 11.382

4.  Ornidazole for prophylaxis of postoperative Crohn's disease recurrence: a randomized, double-blind, placebo-controlled trial.

Authors:  Paul Rutgeerts; Gert Van Assche; Séverine Vermeire; Geert D'Haens; Filip Baert; Maja Noman; Isolde Aerden; Gert De Hertogh; Karel Geboes; Martin Hiele; Andre D'Hoore; Freddy Penninckx
Journal:  Gastroenterology       Date:  2005-04       Impact factor: 22.682

5.  Mesalamine in the maintenance treatment of Crohn's disease: a meta-analysis adjusted for confounding variables.

Authors:  C Cammà; M Giunta; M Rosselli; M Cottone
Journal:  Gastroenterology       Date:  1997-11       Impact factor: 22.682

Review 6.  Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn's Disease.

Authors:  A K Akobeng; E Gardener
Journal:  Cochrane Database Syst Rev       Date:  2005-01-25

7.  5-Aminosalicylic acid (mesalazine) use in Crohn's disease: a survey of the opinions and practice of Australian gastroenterologists.

Authors:  Richard B Gearry; Yousef Ajlouni; Sanjay Nandurkar; John H Iser; Peter R Gibson
Journal:  Inflamm Bowel Dis       Date:  2007-08       Impact factor: 5.325

Review 8.  Efficacy of 5-aminosalicylates in Crohn's disease: systematic review and meta-analysis.

Authors:  Alexander C Ford; Sunanda V Kane; Khurram J Khan; Jean-Paul Achkar; Nicholas J Talley; John K Marshall; Paul Moayyedi
Journal:  Am J Gastroenterol       Date:  2011-03-15       Impact factor: 10.864

Review 9.  The evolving management of postoperative Crohn's disease.

Authors:  Jana G Hashash; Miguel D Regueiro
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2012-09       Impact factor: 3.869

10.  [Integrated management of patients with chronic inflammatory bowel disease in the Rhine-Main Region: results of the first integrated health-care project IBD in Germany].

Authors:  I Blumenstein; W Tacke; N Filmann; C Zosel; H Bock; V Heuzeroth; S Zeuzem; O Schröder
Journal:  Z Gastroenterol       Date:  2013-05-21       Impact factor: 2.000

View more
  8 in total

1.  The use of 5-aminosalicylate for patients with Crohn's disease in a prospective European inception cohort with 5 years follow-up - an Epi-IBD study.

Authors:  Johan Burisch; Daniel Bergemalm; Jonas Halfvarson; Viktor Domislovic; Zeljko Krznaric; Adrian Goldis; Jens F Dahlerup; Pia Oksanen; Pekka Collin; Luisa de Castro; Vicent Hernandez; Svetlana Turcan; Elena Belousova; Renata D'Incà; Alessandro Sartini; Daniela Valpiani; Martina Giannotta; Ravi Misra; Naila Arebi; Dana Duricova; Martin Bortlik; Kelly Gatt; Pierre Ellul; Natalia Pedersen; Jens Kjeldsen; Karina W Andersen; Vibeke Andersen; Konstantinos H Katsanos; Dimitrios K Christodoulou; Shaji Sebastian; Luisa Barros; Fernando Magro; Jóngerð Mm Midjord; Kári R Nielsen; Riina Salupere; Hendrika Al Kievit; Gediminas Kiudelis; Juozas Kupčinskas; Mathurin Fumery; Corinne Gower-Rousseau; Ioannis P Kaimakliotis; Doron Schwartz; Selwyn Odes; Laszlo Lakatos; Peter L Lakatos; Ebbe Langholz; Pia Munkholm
Journal:  United European Gastroenterol J       Date:  2020-07-26       Impact factor: 4.623

Review 2.  Inflammatory Bowel Disease.

Authors:  Jan Wehkamp; Martin Götz; Klaus Herrlinger; Wolfgang Steurer; Eduard F Stange
Journal:  Dtsch Arztebl Int       Date:  2016-02-05       Impact factor: 5.594

3.  Moving from efficacy to effectiveness: budesonide multimatrix in ulcerative colitis.

Authors:  Fernando Magro; Maria Manuela Estevinho
Journal:  United European Gastroenterol J       Date:  2019-09-22       Impact factor: 4.623

4.  Environmental Factors in Romanian and Belgian Patients with Inflammatory Bowel Disease - a Retrospective Comparative Study.

Authors:  Carmen Monica Preda; Teodora Manuc; Doina Istratescu; Edouard Louis; Cristian Baicus; Irina Sandra; Mircea Diculescu; Catherine Reenaers; Catherine van Kemseke; Maria Nitescu; Cristian Tieranu; Corina Georgiana Sandu; Gabriela Oprea-Calin; Letitia Tugui; Siyana Viziru; Cosmin-Alexandru Ciora; Liliana-Simona Gheorghe; Mircea Manuc
Journal:  Maedica (Buchar)       Date:  2019-09

5.  Stopping Mesalamine Therapy in Patients With Crohn's Disease Starting Biologic Therapy Does Not Increase Risk of Adverse Outcomes.

Authors:  Ryan C Ungaro; Berkeley N Limketkai; Camilla Bjørn Jensen; Clara Yzet; Kristine H Allin; Manasi Agrawal; Thomas Ullman; Johan Burisch; Tine Jess; Jean-Frederic Colombel
Journal:  Clin Gastroenterol Hepatol       Date:  2019-08-13       Impact factor: 11.382

6.  Combination of corticosteroids and 5-aminosalicylates or corticosteroids alone for patients with moderate-severe active ulcerative colitis: A global survey of physicians' practice.

Authors:  Shomron Ben-Horin; Jane M Andrews; Konstantinos H Katsanos; Florian Rieder; Flavio Steinwurz; Konstantinos Karmiris; Jae Hee Cheon; Gordon William Moran; Monica Cesarini; Christian D Stone; Doron Schwartz; Marijana Protic; Xavier Roblin; Giulia Roda; Min-Hu Chen; Ofir Har-Noy; Charles N Bernstein
Journal:  World J Gastroenterol       Date:  2017-04-28       Impact factor: 5.742

7.  Trends of 5-Aminosalicylate Medication Use in Patients With Crohn Disease.

Authors:  Mohamed Noureldin; Shirley Cohen-Mekelburg; Asadullah Mahmood; Ryan Stidham; Peter D R Higgins; Shail Govani; Amar R Deshpande; Akbar K Waljee
Journal:  Inflamm Bowel Dis       Date:  2021-03-15       Impact factor: 5.325

8.  Therapeutic preferences and outcomes in newly diagnosed patients with Crohn's diseases in the biological era in Hungary: a nationwide study based on the National Health Insurance Fund database.

Authors:  Zsuzsanna Kurti; Akos Ilias; Lorant Gonczi; Zsuzsanna Vegh; Petra Fadgyas-Freyler; Gyula Korponay; Petra A Golovics; Barbara D Lovasz; Peter L Lakatos
Journal:  BMC Gastroenterol       Date:  2018-01-30       Impact factor: 3.067

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.